Search results for: Precision Medicine
Filter search results
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
In this video, Adrian Towse discusses the challenges and importance of appropriately valuing genomic medicine. He addresses both gene therapies and “pharmacogenomics” — those medicines that will allow targeted, precision…
Personalised Medicine: is it an Oil-Rush or Oil-Spill?
1 May 2020
Personalised medicine, also known as ‘precision’ or ‘stratified’ medicine, targets treatment by using genetics and/or biomarkers to identify patients or subgroups of patients who have distinct mechanisms of disease or…
Reimagining Prevention for a Healthier, More Prosperous Society: Webinar Insights
7 December 2023
…prevention programmes are tailored to the end user, thereby maximising engagement, and efficacy. Precision medicine may catalyse efficiency in prevention. Accessibility of targeted services can be supported by digital health…
Beyond opportunity cost: what are health systems for? The UK–US pharmaceutical agreement and the limits of QALY maximisation
23 October 2026
…to improve the UK commercial environment for medicines taking credit for something that was going to happen anyway. The final, non-binding commitment was around medicines spend. The agreement has often…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions
13 January 2020
…for medicines for more common conditions, may not be appropriate for medicines for ultra-rare conditions. Previous OHE research on availability and access to medicines for rare conditions (also known as…
Value and Cancer: Journal of Cancer Policy Special Issue
25 January 2017
…the value of a prevented fatality. The third article, authored by Professors Adrian Towse and Lou Garrison, focuses on precision cancer medicine. Lou Garrison was recently appointed as an OHE Senior…
OHE Involved in Developing New AMS Report on Stratified Medicines
15 July 2013
…and Economics of Drug Development in 2022. London: Office of Health Economics. Prof Towse’s analysis of valuing stratified/personalised medicine is contained in this short video: Challenges in valuing genomic medicines….
OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting
7 June 2019
…paper, co-authored by Adrian, proposes principles to support dynamic efficiency in the development, adoption, and use of personalised and precision medicine. These principles define the need for a broader concept…
How long are patients WAITing for new treatments?
2 July 2026
…a medicine receiving marketing authorisation (MA), granted by the European Medicines Agency (EMA) or the relevant national authority, and achieving market access in individual countries. Market access is recorded at…